Advocacy intelligence hub — real-time data for patient organizations
ANRS, Emerging Infectious Diseases — PHASE2
ANRS, Emerging Infectious Diseases — PHASE3
Universitätsklinikum Hamburg-Eppendorf — PHASE3
Albert B. Sabin Vaccine Institute — PHASE2
Institute of Tropical Medicine, Belgium — PHASE3
University of Birmingham — PHASE4
EBANGA®: FDA approved
treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Inmazeb
Regeneron
EBANGA�
Emergent Manufacturing Operations Baltimore LLC
EBANGA�
(ansuvimab-zykl)Orphan drugEmergent Manufacturing Operations Baltimore LLC
Pontiano Kaleebu, PhD
MRC/UVRI and LSHTM Uganda Research Unit
Nadine Rouphael, MD
Emory University
📍 ATLANTA, GA
Alison Heald, MD, MD MHS
Sarepta Therapeutics, Inc.
📍 SEATTLE, WA
Richard T Davey, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Martin R Gaudinski, M.D., M.D
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Niankoye Haba, MD
National Blood Transfusion Centre (NBTC), Conakry, Guinea